Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 PDSB | Healthcare | $0.87 | 5.96M | $91.63M | -1.36 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PDSB | PDS Biotechnology | 0.87 | 0.03 | 3.81% |
| Name | Price | % Change | |
|---|---|---|---|
| PDSB | $0.87 | +3.81% |
PDS Biotechnology ( ($PDSB) ) has shared an update. On November 10, 2026, NantWorks exercised outstanding warrants to purchase an aggregate of 17,699,115 PDS Biotech common shares, or pre-funded warrants
Pds Biotechnology (PDSB) is scheduled to report 3rd quarter earnings on 11/12/2026. Regarding Q3 estimates, Wall Street analysts expect Pds Biotechnology to post earnings of -$0.09 per share. Last quarter,
B. Riley raised the firm’s price target on PDS Biotechnology (PDSB) to $4 from $3 and keeps a Buy rating on the shares. PDS Biotechnology’s PDS0301 liver-metastatic colorectal cancer data
PDS Biotechnology ( ($PDSB) ) has issued an announcement. On October 20, 2026, PDS Biotechnology updated its corporate presentation to highlight progress in its oncology pipeline and strategic refocus around
The latest update is out from PDS Biotechnology ( ($PDSB) ). On October 18, 2026, four directors—Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley—resigned from PDS Biotechnology’s board, with
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on PDS Biotechnology. The associated price target remains the same with $5.00. Joseph Pantginis has given his Buy rating
This filing relates to the offer and sale from time to time by the selling stockholders of up to 16.5M shares of common stock. The company is not selling any
Latest data shows the largest indicative borrow rate increases among liquid option names include: PDS Biotechnology Corp (PDSB) 10.40% +6.80, Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.22% +3.70,
Latest data shows the largest indicative borrow rate increases among liquid option names include: Vail Resorts (MTN) 31.04% +26.78, GraniteShares 2x Long IONQ Daily ETF (IONL) 17.47% +3.47, Ruger (RGR)
An announcement from PDS Biotechnology ( ($PDSB) ) is now available. On October 6, 2026, PDS Biotechnology announced it will host a virtual key opinion leader event on October 15,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| PDSB | Apr 1, 2027TBA | $91.63M | $-0.06 | $0.00 | 0.04 | -1.36 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
